SMD100_SAINTMED (SMD100) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of SMD100_SAINTMED stock THB 1.41, price THB 1.52, that is 7.2% below the price, quality 46 out of 100. Rating: fairly valued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 1.07 THB – 10.72 THB · fair‑value band 0.8400 THB – 2.11 THB · the 1.52 THB price screens above the 1.41 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow SMD100_SAINTMED in your weekly email
Every Wednesday you see whether SMD100_SAINTMED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SMD Rise Public Company Limited engages in the import and distribution of medical devices, equipment, and supplies in Thailand. The company is involved in providing sleep testing services; and rental, hire purchase, and leasing of the medical equipment, as well as offers wellness equipment services.
Show moreShow less
It also imports and distributes products related to radiology and other similar medical products. In addition, the company designs and develops software and information technology systems.
Further, it imports and distributes automated medication dispensing machines, pharmaceutical products, medical robots, vascular technologies and equipment, and other related devices.
The company was formerly known as SaintMed Public Company Limited and changed its name to SMD Rise Public Company Limited in January 2025. The company was founded in 1998 and is based in Nonthaburi, Thailand.
Stock analysis
SMD100_SAINTMED (SMD100) currently trades at 1.52 THB, while our model-based Fair Value estimate is 1.41 THB, so the stock looks roughly fairly valued today (gap 7.8%).
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of 3.74 THB per share, and 6 of the 16 models we run sit above the 1.52 THB price.
Bear case: the Earnings-Based group reads lowest at 0.8900 THB, and 10 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.8400 THB (bear) to 2.11 THB (bull), the price of 1.52 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
SMD100_SAINTMED reported revenue of 910M THB in FY2025 versus 1.6B THB in FY2021, a compound −13.4%/yr. Reported net income was 10.6M THB in FY2025, compounding −57.3%/yr from FY2021.
Key figures
Market cap 316M THB (≈ $9.4M) Micro · P/E ratio 6.6 · P/S ratio 0.29 · EPS (TTM) 0.2300 THB · Dividend yield 3.9% · Net margin 4.5% · Return on equity 7.2% · Return on assets (EBIT) 15.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 42% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −7%, SMD100 screens richer than that median.
Fair Value models
Bear0.8400 THBFair Value 1.41 THBBull2.11 THB
Price 1.52 THB · Downside -7.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1458 THB per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−27.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.8%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−31.8% vs −16.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 4%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−7.2% · Below median
Profitability
Return on equity (12 months)7.2% · Above median
Return on assets0.8% · Bottom 25%
Net margin (12 months)4.5% · Top 25%
Operating margin (12 months)10.9% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)99.7% · Top 25%
Dividend yield (12 months)3.9% · Above median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SMD100_SAINTMED Fair Value". https://www.fairvalue-calculator.com/stock/SMD100
Frequently asked questions
Is SMD100_SAINTMED (SMD100) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1.41 THB versus a price of 1.52 THB, about 7% lower (fairly valued).
What is the fair value of SMD100?
Our model-based fair value for SMD100_SAINTMED is 1.41 THB (as of Nov 4, 2026), built from audited fundamentals. The current price: 1.52 THB.
What is the quality score of SMD100?
SMD100_SAINTMED has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SMD100_SAINTMED (SMD100)?
Our model-based price target is the fair value of 1.41 THB (as of Nov 4, 2026) from 16 valuation models. Cautious scenario 0.8400 THB, optimistic scenario 2.11 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the SMD100_SAINTMED stock forecast for 2026?
Our models put fair value at 1.41 THB, about 7% lower versus a price of 1.52 THB (fairly valued). Cautious scenario 0.8400 THB, optimistic scenario 2.11 THB. The calculation is refreshed regularly with new filings.
What is the revenue of SMD100_SAINTMED (SMD100)?
SMD100_SAINTMED reported trailing-twelve-month revenue of about 1.1B THB (latest available figure, as of Nov 4, 2026).
Does SMD100_SAINTMED pay a dividend?
SMD100_SAINTMED currently shows a dividend yield of 3.95% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of SMD100_SAINTMED (SMD100) and when is the ex-dividend date?
SMD100_SAINTMED pays a dividend of 0.06 THB per share a year, a dividend yield of 3.9%. The last ex-dividend date was May 8, 2026. A dividend has been paid every year since at least 2022. The payout ratio is 26.1% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of SMD100_SAINTMED (SMD100)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SMD100_SAINTMED it is 1.41 THB per share (as of Nov 4, 2026), against a price of 1.52 THB. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is SMD100_SAINTMED stock overvalued or undervalued in 2026?
As of Nov 4, 2026, SMD100 trades above its calculated fair value: price 1.52 THB, fair value 1.41 THB, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMD100?
No. The price is what the market pays today (1.52 THB); the fair value is what the company's own numbers justify (1.41 THB). For SMD100_SAINTMED the two are 0.1100 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is SMD100_SAINTMED worth?
The market values SMD100_SAINTMED at about 316M THB (market capitalisation, as of Nov 4, 2026). Per share that is 1.52 THB; our models calculate a fair value of 1.41 THB per share.
What do the bullish and bearish scenarios say about SMD100?
Our models span a range for SMD100_SAINTMED: cautious scenario 0.8400 THB, base 1.41 THB, optimistic 2.11 THB per share (as of Nov 4, 2026, price 1.52 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SMD100?
SMD100_SAINTMED trades at a price-to-earnings ratio of 6.6 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.41 THB is built from several models across several years. Other multiples: P/B 0.4, P/S 0.3, EV/EBITDA 2.4.
How solid is the balance sheet of SMD100_SAINTMED (SMD100)?
Balance-sheet figures for SMD100_SAINTMED (as of Nov 4, 2026): return on equity 7.2%, debt of 0.04 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is SMD100 from its 52-week high?
SMD100_SAINTMED trades at 1.52 THB, about 45% below its 52-week high of 2.77 THB and 42% above the low of 1.07 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1.41 THB is for.
Which stocks are comparable to SMD100_SAINTMED?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SMD100_SAINTMED stock attractive at the current price?
The data as of Nov 4, 2026: price 1.52 THB, calculated fair value 1.41 THB (−7%), Quality Score 46/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SMD100 calculated?
We run SMD100_SAINTMED through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.41 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. SMD100_SAINTMED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SMD100_SAINTMED (SMD100)?
The closing price on Nov 6, 2026 was 1.52 THB. Our model-based fair value is 1.41 THB, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SMD100_SAINTMED right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (0.8400 THB to 2.11 THB) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of SMD100_SAINTMED
How large is the market capitalisation of SMD100_SAINTMED (SMD100)?
The market capitalisation of SMD100_SAINTMED is 316M THB (≈ $9.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SMD100_SAINTMED (SMD100)?
The price-to-sales ratio of SMD100_SAINTMED is 0.29 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SMD100_SAINTMED (SMD100)?
Earnings per share at SMD100_SAINTMED are 0.2300 THB (price ÷ EPS = P/E 6.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SMD100_SAINTMED (SMD100)?
The dividend yield of SMD100_SAINTMED is 3.9% (payout 26.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SMD100_SAINTMED (SMD100)?
The net margin of SMD100_SAINTMED is 4.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SMD100_SAINTMED (SMD100)?
The return on equity (ROE) of SMD100_SAINTMED is 7.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SMD100_SAINTMED (SMD100)?
On an EBIT basis the return on assets of SMD100_SAINTMED is 15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SMD100_SAINTMED (SMD100)?
The operating margin of SMD100_SAINTMED is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SMD100_SAINTMED (SMD100)?
Revenue at SMD100_SAINTMED is growing +99.7% versus a year earlier (3y avg −23.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SMD100_SAINTMED (SMD100)?
Earnings per share at SMD100_SAINTMED are growing +21.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SMD100_SAINTMED (SMD100) generate?
The free cash flow of SMD100_SAINTMED is −153M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SMD100_SAINTMED (SMD100) carry?
The net debt of SMD100_SAINTMED is 193M THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SMD100_SAINTMED in the live analysis
One click puts SMD100_SAINTMED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026